
Menu





Eureka Therapeutics Announces Successful Preclinical Results of InvisiMask™ Human Antibody Nasal Spray Against SARS-CoV-2 Infection
December 14, 2020
– NEWLY PUBLISHED STUDY REPORTS INVISIMASK™, A SELF-ADMINISTERED NASAL SPRAY, PROTECTS AGAINST SARS-COV-2 INFECTION FOR UP TO 10 HOURS IN MICE – INVISIMASK HUMAN ANTIBODY NASAL
Eureka Therapeutics Appoints Nobel Laureate Randy Schekman, Ph.D. to its Scientific Advisory Board
November 9, 2020
Emeryville, California, November 9, 2020 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, announced today that
Eureka Therapeutics to Present at Two Upcoming Virtual Conferences
October 13, 2020
Emeryville, California, October 13, 2020 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced
Eureka Therapeutics Announces Initiation of ARYA-1 Clinical Trial to Evaluate ET140203 ARTEMIS® T Cell Therapy in Hepatocellular Carcinoma
October 5, 2020
Emeryville, California, October 5, 2020 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced

